MA39342B2 - Anticorps il -21 - Google Patents
Anticorps il -21Info
- Publication number
- MA39342B2 MA39342B2 MA39342A MA39342A MA39342B2 MA 39342 B2 MA39342 B2 MA 39342B2 MA 39342 A MA39342 A MA 39342A MA 39342 A MA39342 A MA 39342A MA 39342 B2 MA39342 B2 MA 39342B2
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- methods
- compositions
- antibody
- antagonism
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des anticorps humanisés construits qui ont une forte affinité de liaison pour il -21 humain et qui le neutralisent, des procédés d'utilisation desdits anticorps pour traiter des maladies dans lesquelles l'antagonisme ou la neutralisation des effets d'il -21 est garanti, telles que des maladies auto-immunes, des compositions et des procédés de production par recombinaison des anticorps, et des compositions pharmaceutiques comprenant lesdits anticorps.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968550P | 2014-03-21 | 2014-03-21 | |
| PCT/US2015/020383 WO2015142637A1 (fr) | 2014-03-21 | 2015-03-13 | Anticorps il -21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39342A1 MA39342A1 (fr) | 2018-03-30 |
| MA39342B2 true MA39342B2 (fr) | 2020-03-31 |
Family
ID=54141466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39342A MA39342B2 (fr) | 2014-03-21 | 2015-03-13 | Anticorps il -21 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9394362B2 (fr) |
| EP (1) | EP3119806B1 (fr) |
| JP (2) | JP6053989B2 (fr) |
| KR (1) | KR101859857B1 (fr) |
| CN (1) | CN106061999B (fr) |
| AP (1) | AP2016009450A0 (fr) |
| AR (1) | AR099625A1 (fr) |
| AU (1) | AU2015231777B2 (fr) |
| BR (1) | BR112016019176A2 (fr) |
| CA (1) | CA2939543C (fr) |
| CL (1) | CL2016002281A1 (fr) |
| EA (1) | EA033335B1 (fr) |
| EC (1) | ECSP16075416A (fr) |
| ES (1) | ES2774422T3 (fr) |
| IL (1) | IL246909A0 (fr) |
| MA (1) | MA39342B2 (fr) |
| MX (1) | MX2016012120A (fr) |
| MY (1) | MY177915A (fr) |
| NZ (1) | NZ722518A (fr) |
| PE (1) | PE20161221A1 (fr) |
| PH (1) | PH12016501820A1 (fr) |
| SG (1) | SG11201606705QA (fr) |
| TW (1) | TWI646105B (fr) |
| WO (1) | WO2015142637A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913627TA (en) | 2014-04-08 | 2020-03-30 | Boston Pharmaceuticals Inc | Binding molecules specific for il-21 and uses thereof |
| CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
| CA3018792C (fr) * | 2016-03-31 | 2023-03-28 | Eli Lilly And Company | Anticorps contre il-21 et leurs utilisations |
| WO2019229711A1 (fr) * | 2018-05-31 | 2019-12-05 | Glycom A/S | Mélange de hmos pour le traitement de maladies auto-immunes |
| JP2021530243A (ja) | 2018-07-25 | 2021-11-11 | アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. | 新規ｉｌ−２１プロドラッグおよびそれを使用する方法 |
| WO2020028832A1 (fr) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020252264A1 (fr) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation |
| JP2022545439A (ja) | 2019-08-21 | 2022-10-27 | アスクジーン・ファーマ・インコーポレイテッド | 新規ｉｌ－２１プロドラッグおよびその使用方法 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024525613A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP4366784A1 (fr) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Complexes ciblant le muscle et formulations de traitement de dystrophinopathies |
| MX2024000494A (es) * | 2021-07-09 | 2024-04-10 | Dyne Therapeutics Inc | Complejos dirigidos al tratamiento de musculos, y usos de los mismos para tratar distrofinopatías. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| DE602004025332D1 (de) | 2003-03-14 | 2010-03-18 | Wyeth Corp | Antikörper gegen il21-rezeptor und deren verwendung |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| CA2632218A1 (fr) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Antagonistes du recepteur de il-21 |
| PL1963369T3 (pl) * | 2005-11-28 | 2013-10-31 | Zymogenetics Inc | Antagoniści IL-21 |
| US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| ES2660036T3 (es) * | 2007-12-07 | 2018-03-20 | Zymogenetics, Inc. | Moléculas de anticuerpo humanizadas específicas para IL-31 |
| AU2008364115B2 (en) * | 2007-12-07 | 2013-11-21 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| WO2012098113A1 (fr) | 2011-01-17 | 2012-07-26 | Novo Nordisk A/S | Ligands il-21 |
| US20140170153A1 (en) * | 2011-05-31 | 2014-06-19 | Novo Nordisk A/S | Il-21 epitope and il-21 ligands |
-
2015
- 2015-03-04 AR ARP150100643A patent/AR099625A1/es unknown
- 2015-03-06 TW TW104107331A patent/TWI646105B/zh not_active IP Right Cessation
- 2015-03-13 CA CA2939543A patent/CA2939543C/fr active Active
- 2015-03-13 AP AP2016009450A patent/AP2016009450A0/en unknown
- 2015-03-13 MY MYPI2016703395A patent/MY177915A/en unknown
- 2015-03-13 BR BR112016019176A patent/BR112016019176A2/pt not_active Application Discontinuation
- 2015-03-13 ES ES15764397T patent/ES2774422T3/es active Active
- 2015-03-13 EP EP15764397.4A patent/EP3119806B1/fr active Active
- 2015-03-13 PE PE2016001575A patent/PE20161221A1/es unknown
- 2015-03-13 US US14/657,075 patent/US9394362B2/en active Active
- 2015-03-13 EA EA201691521A patent/EA033335B1/ru not_active IP Right Cessation
- 2015-03-13 CN CN201580012207.3A patent/CN106061999B/zh active Active
- 2015-03-13 JP JP2016514173A patent/JP6053989B2/ja active Active
- 2015-03-13 SG SG11201606705QA patent/SG11201606705QA/en unknown
- 2015-03-13 WO PCT/US2015/020383 patent/WO2015142637A1/fr not_active Ceased
- 2015-03-13 KR KR1020167025492A patent/KR101859857B1/ko not_active Expired - Fee Related
- 2015-03-13 AU AU2015231777A patent/AU2015231777B2/en not_active Ceased
- 2015-03-13 MX MX2016012120A patent/MX2016012120A/es unknown
- 2015-03-13 MA MA39342A patent/MA39342B2/fr unknown
- 2015-03-13 NZ NZ722518A patent/NZ722518A/en not_active IP Right Cessation
-
2016
- 2016-07-24 IL IL246909A patent/IL246909A0/en unknown
- 2016-09-09 CL CL2016002281A patent/CL2016002281A1/es unknown
- 2016-09-19 PH PH12016501820A patent/PH12016501820A1/en unknown
- 2016-09-20 EC ECIEPI201675416A patent/ECSP16075416A/es unknown
- 2016-11-29 JP JP2016231655A patent/JP6373944B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39342B2 (fr) | Anticorps il -21 | |
| WO2018069500A3 (fr) | Anticorps anti-lag-3 et compositions | |
| MA42622B1 (fr) | Agents de liaison à tigit et leurs utilisations | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| WO2018017864A3 (fr) | Agents de liaison à pvrig et leurs utilisations | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| MA44322A (fr) | Compositions comprenant des souches bactériennes | |
| EA201792047A1 (ru) | Новые соединения | |
| EP3411504A4 (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| MA40755B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA40754B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA41060B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA55434B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA49726B1 (fr) | Formulation d'anticorps anti-cgrp | |
| MA41010B1 (fr) | Compositions comprenant des souches bactériennes | |
| MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
| MA45125B1 (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| WO2015132675A3 (fr) | Procédés et compositions pour modifier une réponse immunitaire | |
| MY199683A (en) | Anti-pd-1 antibodies | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| WO2017049038A3 (fr) | Anticorps anti-cd115 | |
| MX2017001038A (es) | Variantes de proteina de unión al factor h y metodos de uso de estas. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. |